Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade B 30.18 -4.16% -1.31
IMMU closed down 4.16 percent on Thursday, June 4, 2020, on 80 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical IMMU trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -4.16%
BB Squeeze Ended Range Expansion -4.16%
20 DMA Support Bullish -9.69%
Bollinger Band Squeeze Range Contraction -9.69%
20 DMA Support Bullish -9.69%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Serious Diseases Pancreatic Cancer Non Hodgkin Lymphoma Humanized Antibody Leukemias Lupus NHL Cd20 Diabetic Foot Ulcers Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma Treatment Of Pancreatic Cancer

Is IMMU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 35.47
52 Week Low 8.8
Average Volume 5,568,305
200-Day Moving Average 19.17
50-Day Moving Average 26.06
20-Day Moving Average 33.16
10-Day Moving Average 33.28
Average True Range 1.76
ADX 41.06
+DI 21.09
-DI 24.28
Chandelier Exit (Long, 3 ATRs ) 30.19
Chandelier Exit (Short, 3 ATRs ) 34.83
Upper Bollinger Band 35.45
Lower Bollinger Band 30.86
Percent B (%b) -0.15
BandWidth 13.86
MACD Line 1.44
MACD Signal Line 2.32
MACD Histogram -0.8762
Fundamentals Value
Market Cap 3.36 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -20.53
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.85
Resistance 3 (R3) 34.05 33.02 33.24
Resistance 2 (R2) 33.02 32.09 32.92 33.03
Resistance 1 (R1) 31.60 31.51 31.09 31.40 32.83
Pivot Point 30.58 30.58 30.32 30.48 30.58
Support 1 (S1) 29.16 29.64 28.64 28.96 27.53
Support 2 (S2) 28.13 29.06 28.03 27.33
Support 3 (S3) 26.71 28.13 27.12
Support 4 (S4) 26.51